- Laurus Labs posts Q2 net profit of ₹195 crore, up from ₹20 crore year-on-year, with revenue increasing 35% to ₹1,653 crore.
- The Hyderabad-based company continues to expand its CDMO business, invest in ADC technologies, and secure land for future manufacturing growth.
Laurus Labs, the Hyderabad-based pharmaceutical and contract development and manufacturing organisation (CDMO), reported a substantial increase in its consolidated net profit for the second quarter ended September 2025. Profit jumped to ₹195 crore, compared with ₹20 crore in the same period last year. Revenue rose 35% to ₹1,653 crore from ₹1,224 crore a year earlier.
The growth was driven by Laurus Labs’ ongoing expansion in its CDMO business, complemented by continued strength in its generics portfolio. Satyanarayana Chava, Founder and CEO, said the results reflect “ongoing expansion of CDMO business, supported by sustained growth in generics.”
In addition to operational growth, Laurus Labs announced a strategic investment of $2 million in Aarvik Therapeutics. This investment provides access to novel antibody-drug conjugate (ADC) technology and pipeline, supporting the company’s integrated ADC service offerings.
Earlier in the quarter, Laurus also received land allocation from the Andhra Pradesh government to facilitate future business expansion. The company plans to augment its manufacturing scale and introduce new technologies at the site.
“Going ahead, we will retain our focus to invest in high-value CDMO/CMO business opportunities to drive near-term and long-term growth and returns for our shareholders.”
VV Ravi Kumar, Executive Director and CFO
